VEGFA and type 2 diabetes mellitus: Therefore, its activity depends on genetic polymorphism besides some pathological activators, and its levels are strongly related to the deterioration of systemic diseases such as T2DM and consequential implications on NVG representing directions for new research projects due to anti-VEGF treatment in terms of dose titration which provides better efficacy of anti-VEGF treatment [14,15].